Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 400-405

  Miwa, Kaori ^a   Tanaka, Makiko ^a   Okazaki, Shuhei ^a   Furukado, Shigetaka ^a   Sakaguchi, Manabu ^a   Mochizuki, Hideki ^a   Kitagawa, Kazuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cerebrovascular disease prevention; epidemiology; inflammation; interleukin (IL) 6; risk factors

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 18; INTERLEUKIN 6;

AGED; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; ULTRASOUND; VASCULAR DISEASE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; INTERLEUKIN-18; INTERLEUKIN-6; JAPAN; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE, LACUNAR; TIME FACTORS;

EID: 84872898083     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300350     Document Type: Article

References (36)

1. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
3. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
4. Blankenberg S, Luc G, Ducimetière P, Arveiler D, Ferrières J, Amouyel P, Evans A, Cambien F, Tiret L, PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-2459.
5. Simon A, Megnien JL, Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol. 2010;30:182-185.
6. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611-619.
7. van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, Hofman A, Witteman JC. Infammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2002;22:838-842.
8. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, Tracy RP, Longstreth WT Jr. Biomarkers of infammation and MRI-defned small vessel disease of the brain: the Cardiovascular Health Study. Stroke. 2008;39:1952-1959.
9. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170.
10. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K. Low-grade infammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke. 2007;38:911-917.
11. Danesh J, Wheeler JG, Hirschfeld GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of infammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
12. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368-1373.
13. Herder C, Schöttker B, Rothenbacher D, Roden M, Kolb H, Müller H, Brenner H. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Atherosclerosis. 2011;216:244-247.
14. Kitagawa K, Hougaku H, Yamagami H, Hashimoto H, Itoh T, Shimizu Y, et al. Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis. 2007;24:35-42.
15. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Kitagawa K. Relations of blood infammatory marker levels with cerebral micro-bleeds. Stroke. 2011;42:3202-3206.
16. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
17. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relation between interleukin-6 level and subclinical intracranial large-artery atherosclerosis. Atherosclerosis. 2008;197:326-332.
18. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, Hori M. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol. 2005;25:1458-1462.
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifcation and beyond. Stat Med. 2008;27:157-172.
20. Pikula A, Beiser AS, DeCarli C, Himali JJ, Debette S, Au R, Selhub J, Toffer GH, Wang TJ, Meigs JB, Kelly-Hayes M, Kase CS, Wolf PA, Vasan RS, Seshadri S. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation. 2012;125:2100-2107.
21. Sattar N, Murray HM, Welsh P, Blauw GJ, Buckley BM, Cobbe S, et al. Are markers of infammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med. 2009;6:e1000099.
22. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD. The associations of interleukin-6 (IL-6) and downstream infamma-tory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis. 2010;209:551-557.
23. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Infammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317-2322.
24. Stott DJ, Welsh P, Rumley A, Robertson M, Ford I, Sattar N, Westendorp RG, Jukema JW, Cobbe SM, Lowe GD. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol. 2009;38:253-261.
25. Welsh P, Lowe GD, Chalmers J, Campbell DJ, Rumley A, Neal BC, MacMahon SW, Woodward M. Associations of proinfammatory cyto-kines with the risk of recurrent stroke. Stroke. 2008;39:2226-2230.
26. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Association of circulating infamma-tory markers with recurrent vascular events after stroke: a prospective cohort study. Stroke. 2011;42:10-16.
27. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Infammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med. 2009;6:e1000145.
28. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
29. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345-2352.
30. Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC, Sacco RL. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology. 2009;73:1300-1307.
31. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
32. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
33. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213.
34. Hingorani AD, Casas JP; Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214-1224.
35. Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
36. Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M, Lennon LT, Thomson A, Welsh P, Rumley A, Lowe GD, Whincup PH. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011;217:227-233.